RenovoRx, Inc.
About RenovoRx, Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.1M
- Net income
- -$11.2M
- Total assets
- $8.1M
- Market cap
- $39.3M
- Gross margin
- 70.9%
- Operating margin
- -1114.0%
- Net margin
- -994.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.1M
- Cost of revenue
- $327.0K
- Gross profit
- $796.0K
- Operating expenses
- $13.3M
- Operating income
- -$12.5M
- Income tax
- $2.0K
- Net income
- -$11.2M
- EPS (basic)
- $-0.32
- EPS (diluted)
- $-0.32
Balance sheet
- Total assets
- $8.1M
- Current assets
- $7.9M
- Total liabilities
- $2.7M
- Current liabilities
- $2.0M
- Shareholders’ equity
- $5.4M
Cash flow
- Operating cash flow
- -$11.0M
- Investing cash flow
- -$2.0K
- Financing cash flow
- $10.8M
- Net cash flow
- -$130.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $39.3M
- EPS (diluted)
- $-0.32
- Shares outstanding
- 44.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 26, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $11.2M in FY2025.
- Revenue grew 235% from FY2021 to FY2025.
- Gross margin of 70.9%, net margin -994.5%.
- Trading 37% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review RenovoRx, Inc..
Write a review
News about RenovoRx, Inc.
News & sentiment via Polygon.io
